Cartesian Therapeutics (RNAC) Return on Equity (2016 - 2025)
Historic Return on Equity for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 4.36%.
- Cartesian Therapeutics' Return on Equity rose 2200.0% to 4.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.36%, marking a year-over-year increase of 2200.0%. This contributed to the annual value of 0.35% for FY2024, which is 9200.0% down from last year.
- Cartesian Therapeutics' Return on Equity amounted to 4.36% in Q3 2025, which was up 2200.0% from 6.52% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Return on Equity high stood at 12.07% for Q4 2024, and its period low was 7.26% during Q4 2021.
- Its 5-year average for Return on Equity is 1.88%, with a median of 1.27% in 2023.
- In the last 5 years, Cartesian Therapeutics' Return on Equity tumbled by -3253400bps in 2021 and then skyrocketed by 108000bps in 2024.
- Over the past 5 years, Cartesian Therapeutics' Return on Equity (Quarter) stood at 7.26% in 2021, then skyrocketed by 103bps to 0.24% in 2022, then surged by 430bps to 1.27% in 2023, then surged by 849bps to 12.07% in 2024, then crashed by -64bps to 4.36% in 2025.
- Its Return on Equity was 4.36% in Q3 2025, compared to 6.52% in Q2 2025 and 3.09% in Q1 2025.